GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » YoY EBITDA Growth

Idorsia (LTS:0RQE) YoY EBITDA Growth : -137.11% (As of Sep. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Idorsia YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Idorsia's YoY EBITDA Growth for the quarter that ended in Sep. 2024 was -137.11%.

Idorsia's EBITDA per Share for the three months ended in Sep. 2024 was CHF-0.49.

Idorsia YoY EBITDA Growth Historical Data

The historical data trend for Idorsia's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia YoY EBITDA Growth Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -26.98 16.57 -18.68 -26.27 67.64

Idorsia Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 215.34 40.42 114.73 45.95 -137.11

Idorsia YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Idorsia's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-1.428--4.413)/ | -4.413 |
=67.64 %

Idorsia's YoY EBITDA Growth for the quarter that ended in Sep. 2024 is calculated as:

YoY EBITDA Growth (Q: Sep. 2024 )
=(EBITDA per Share (Q: Sep. 2024 )-EBITDA per Share (Q: Sep. 2023 )) / | EBITDA per Share (Q: Sep. 2023 )) |
=(-0.494-1.331)/ | 1.331 |
=-137.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Idorsia's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » YoY EBITDA Growth
Comparable Companies
XSWX:XLS XSWX:BSLN XSWX:SANN XSWX:MOLN XSWX:NWRN XSWX:RLF XSWX:EVE XSWX:SPEX XSWX:OBSN XSWX:ADXN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
IDRSF:USA IDIAz:UK IDIA:Switzerland
Address
Hegenheimermattweg 91, Allschwil, CHE, 4123
Website
https://www.idorsia.com
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia Headlines

No Headlines